On the other hand, Feng et al. [31] detected a lower expression of ISGs in patients with active MS and found that this was linked to a subnormal phosphorylation of the transcription factor (TF) STAT1. They concluded that a defect in type I IFN signaling may predict the course of disease and responses to therapy. The gene discussed is STAT1; the disease is myeloid sarcoma.